MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1245/s10434-025-18475-3

Медицинская библиотека · Annals of surgical oncology · 2025

International Survey on Evidence for Index Lymph Node Surgery After Neoadjuvant Systemic Therapy for Stage III Melanoma.

Novis Elan, Rautalin Mervi, Amaria Rodabe N, Ascierto Paolo A, Blank Christian U, Faries Mark B, Grunhagen Dirk J, Gyorki David E, Hayes Andrew J, Kuijpers Anke M J, Long Georgina V, Mammen Joshua M V, Menzies Alexander M, Ross Merrick I, Rutkowski Piotr, Tawbi Hussein A, Tetzlaff Michael T, Zager Jonathan S, Wargo Jennifer A, Hieken Tina J, van Akkooi Alexander C J, International Neoadjuvant Melanoma Consortium (INMC)

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Neoadjuvant immunotherapy for resectable stage III melanoma has demonstrated promising outcomes in recent trials, prompting a change in clinical practice in many countries. Although therapeutic lymph node dissection (TLND) remains the standard of care after neoadjuvant treatment, a less invasive index lymph node (ILN)-guided approach has been proposed. The global melanoma community's acceptance of neoadjuvant immunotherapy and the need for TLND or ILN after this remains unclear.

METHODS

A two-stage international survey was conducted among melanoma experts between May 2023 and January 2025. Respondents were asked about their familiarity with neoadjuvant trials, current practices, and opinions on ILN versus TLND before and after publication of the NADINA trial.

RESULTS

The response rates were 50% (118/237) in the first survey and 62% (148/237) in the second survey. In the second survey, 74% of the respondents considered neoadjuvant therapy the standard of care, and support for ILN-guided surgery rose from 27 to 40% between the surveys. However, 54% still favored a phase 3 randomized controlled trial before changing the clinical practice guidelines, and only 27% believed the current data were sufficient for adoption of ILN as standard. Key barriers included concerns about oncologic safety, pathologic standardization, and patient selection.

CONCLUSION

The current evidence supports the use of neoadjuvant immunotherapy as the standard of care for stage III melanoma. However, widespread clinical adoption of ILN-guided surgical de-escalation remains limited. A multicenter phase 3 trial (MSLT-3), launching in 2025, is expected to provide important data to guide future practice.

Для цитирования: Novis Elan, Rautalin Mervi, Amaria Rodabe N, Ascierto Paolo A, Blank Christian U, Faries Mark B, Grunhagen Dirk J, Gyorki David E, Hayes Andrew J, Kuijpers Anke M J, Long Georgina V, Mammen Joshua M V, Menzies Alexander M, Ross Merrick I, Rutkowski Piotr, Tawbi Hussein A, Tetzlaff Michael T, Zager Jonathan S, Wargo Jennifer A, Hieken Tina J, van Akkooi Alexander C J, International Neoadjuvant Melanoma Consortium (INMC). International Survey on Evidence for Index Lymph Node Surgery After Neoadjuvant Systemic Therapy for Stage III Melanoma.. Annals of surgical oncology. 2025. DOI: 10.1245/s10434-025-18475-3.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.